Hyaluronic acid-human blood hydrogels for stem cell transplantation
Published by Elsevier Ltd..
Tissue engineering-based approaches have the potential to improve stem cell engraftment by increasing cell delivery to the myocardium. Our objective was to develop and characterize a naturally-derived, autologous, biodegradable hydrogel in order to improve acute stem cell retention in the myocardium. HA-blood hydrogels (HA-BL) were synthesized by mixing in a 1:1(v/v) ratio, lysed whole blood and hyaluronic acid (HA), whose carboxyl groups were functionalized with N-hydroxysuccinimide (NHS) to yield HA succinimidyl succinate (HA-NHS). We performed physical characterization and measured survival/proliferation of cardiosphere-derived cells (CDCs) encapsulated in the hydrogels. Hydrogels were injected intra-myocardially or applied epicardially in rats. NHS-activated carboxyl groups in HA react with primary amines present in blood and myocardium to form amide bonds, resulting in a 3D hydrogel bound to tissue. HA-blood hydrogels had a gelation time of 58±12 s, swelling ratio of 10±0.5, compressive and elastic modulus of 14±3 and 1.75±0.6 kPa respectively. These hydrogels were not degraded at 4 wks by hydrolysis alone. CDC encapsulation promoted their survival and proliferation. Intra-myocardial injection of CDCs encapsulated in these hydrogels greatly increased acute myocardial retention (p=0.001). Epicardial application of HA-blood hydrogels improved left ventricular ejection fraction following myocardial infarction (p=0.01). HA-blood hydrogels are highly adhesive, biodegradable, promote CDC survival and increase cardiac function following epicardial application after myocardial infarction.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2012 |
|---|---|
| Erschienen: |
2012 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
|---|---|
| Enthalten in: |
Biomaterials - 33(2012), 32 vom: 16. Nov., Seite 8026-33 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chang, Connie Y [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9004-61-9 |
|---|
| Anmerkungen: |
Date Completed 16.01.2013 Date Revised 21.10.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.biomaterials.2012.07.058 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM220277435 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM220277435 | ||
| 003 | DE-627 | ||
| 005 | 20231224045043.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2012 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.biomaterials.2012.07.058 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0734.xml |
| 035 | |a (DE-627)NLM220277435 | ||
| 035 | |a (NLM)22898181 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chang, Connie Y |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hyaluronic acid-human blood hydrogels for stem cell transplantation |
| 264 | 1 | |c 2012 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.01.2013 | ||
| 500 | |a Date Revised 21.10.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Published by Elsevier Ltd. | ||
| 520 | |a Tissue engineering-based approaches have the potential to improve stem cell engraftment by increasing cell delivery to the myocardium. Our objective was to develop and characterize a naturally-derived, autologous, biodegradable hydrogel in order to improve acute stem cell retention in the myocardium. HA-blood hydrogels (HA-BL) were synthesized by mixing in a 1:1(v/v) ratio, lysed whole blood and hyaluronic acid (HA), whose carboxyl groups were functionalized with N-hydroxysuccinimide (NHS) to yield HA succinimidyl succinate (HA-NHS). We performed physical characterization and measured survival/proliferation of cardiosphere-derived cells (CDCs) encapsulated in the hydrogels. Hydrogels were injected intra-myocardially or applied epicardially in rats. NHS-activated carboxyl groups in HA react with primary amines present in blood and myocardium to form amide bonds, resulting in a 3D hydrogel bound to tissue. HA-blood hydrogels had a gelation time of 58±12 s, swelling ratio of 10±0.5, compressive and elastic modulus of 14±3 and 1.75±0.6 kPa respectively. These hydrogels were not degraded at 4 wks by hydrolysis alone. CDC encapsulation promoted their survival and proliferation. Intra-myocardial injection of CDCs encapsulated in these hydrogels greatly increased acute myocardial retention (p=0.001). Epicardial application of HA-blood hydrogels improved left ventricular ejection fraction following myocardial infarction (p=0.01). HA-blood hydrogels are highly adhesive, biodegradable, promote CDC survival and increase cardiac function following epicardial application after myocardial infarction | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Hydrogels |2 NLM | |
| 650 | 7 | |a Succinimides |2 NLM | |
| 650 | 7 | |a Hyaluronic Acid |2 NLM | |
| 650 | 7 | |a 9004-61-9 |2 NLM | |
| 650 | 7 | |a N-hydroxysuccinimide |2 NLM | |
| 650 | 7 | |a MJE3791M4T |2 NLM | |
| 700 | 1 | |a Chan, Angel T |e verfasserin |4 aut | |
| 700 | 1 | |a Armstrong, Patrick A |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Hong-Chang |e verfasserin |4 aut | |
| 700 | 1 | |a Higuchi, Takahiro |e verfasserin |4 aut | |
| 700 | 1 | |a Strehin, Iossif A |e verfasserin |4 aut | |
| 700 | 1 | |a Vakrou, Styliani |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Xiaoping |e verfasserin |4 aut | |
| 700 | 1 | |a Brown, Sophia N |e verfasserin |4 aut | |
| 700 | 1 | |a O'Rourke, Brian |e verfasserin |4 aut | |
| 700 | 1 | |a Abraham, Theodore P |e verfasserin |4 aut | |
| 700 | 1 | |a Wahl, Richard L |e verfasserin |4 aut | |
| 700 | 1 | |a Steenbergen, Charles J |e verfasserin |4 aut | |
| 700 | 1 | |a Elisseeff, Jennifer H |e verfasserin |4 aut | |
| 700 | 1 | |a Abraham, M Roselle |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biomaterials |d 1989 |g 33(2012), 32 vom: 16. Nov., Seite 8026-33 |w (DE-627)NLM012732516 |x 1878-5905 |7 nnns |
| 773 | 1 | 8 | |g volume:33 |g year:2012 |g number:32 |g day:16 |g month:11 |g pages:8026-33 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.biomaterials.2012.07.058 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 33 |j 2012 |e 32 |b 16 |c 11 |h 8026-33 | ||